Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,421 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02833610 | A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency | completed | Phase 2 | 55 | Massachusetts General HospitalOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT05804032 | Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 3 | 514 | University of Heidelberg Medical CenterOTHER | 2 | Feb 18, 2026 |
| clinicaltrials |
| NCT05561751 | Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant | completed | Phase 2 | 30 | GPCR Therapeutics, Inc.INDUSTRY | 1 | Feb 12, 2026 | clinicaltrials |
| NCT04322292 | A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma | completed | Phase 1 | 9 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT05014412 | A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment(MagnetisMM-9) | completed | Phase 2 | 86 | PfizerINDUSTRY | 4 | Feb 10, 2026 | clinicaltrials |
| NCT03275285 | Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients(IKEMA) | completed | Phase 3 | 302 | SanofiINDUSTRY | 16 | Feb 9, 2026 | clinicaltrials |
| NCT04674813 | A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 | 130 | Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY | 1 | Feb 9, 2026 | clinicaltrials |
| NCT01237054 | Imaging in MGUS, SMM and MM | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Feb 6, 2026 | clinicaltrials |
| NCT01745640 | Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)(IFM2010-02) | completed | Phase 2 | 63 | University Hospital, LilleOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03275103 | Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) | completed | Phase 1 | 355 | Genentech, Inc.INDUSTRY | 4 | Feb 5, 2026 | clinicaltrials |
| NCT05918185 | Evaluation of Comprehensive Geriatric Assessment and Laboratory Biomarkers in Elderly Patients With Multiple Myeloma | completed | — | 56 | Mayo ClinicOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT02407509 | Phase I Trial of VS-6766 Alone and in Combination With Everolimus(RAF/MEK) | completed | Phase 1 | 104 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT03159702 | Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation | completed | Phase 2 | 43 | Medical College of WisconsinOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT02389517 | Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant | completed | Phase 2 | 42 | University of ChicagoOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07354191 | Outcome of Multiple Myeloma Associated With Autoimmune Hemolytic Anemia | completed | N/A | 66 | New Valley UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT02969837 | Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma | completed | Phase 2 | 46 | University of ChicagoOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT05063591 | Removing Transfusion Dependence as a Barrier to Hospice Enrollment(BRUOG-407) | completed | N/A | 18 | Adam OlszewskiOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT02441686 | Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 46 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05625971 | Non-invasive MRD Assessment in Multiple Myeloma(NIRVANA) | completed | — | 36 | Rajshekhar Chakraborty, MDOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT01208766 | Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma(HO95) | completed | Phase 3 | 1,503 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 16 | Jan 6, 2026 | clinicaltrials |
| NCT03702725 | Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 14 | Alliance Foundation Trials, LLC.OTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05355987 | Impact of Paramedical Consultations in Oncological Supportive Care in Outpatients With Multiple Myeloma(SOSAM) | completed | N/A | 20 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04952766 | Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults(EREVA) | completed | Phase 4 | 196 | Centre Hospitalier Régional d'OrléansOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT01665794 | Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 25 | University of ChicagoOTHER | 2 | Dec 22, 2025 | clinicaltrials |
| NCT00466674 | Treatment of Myeloma in Patients <= 65 Years Old With Response >= 50% After HSC Autotransplant by Allogenic Transplant Genoidentical or Phenoidentical After Reduced Intensity Conditioning(IFM 2005-03) | completed | Phase 2 | 13 | Hospices Civils de LyonOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT03180736 | Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex(EMN14) | completed | Phase 3 | 304 | Stichting European Myeloma NetworkNETWORK | 10 | Dec 19, 2025 | clinicaltrials |
| NCT03631043 | Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma | completed | Early Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT02461888 | Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.(MUKEight) | completed | Phase 2 | 112 | University of LeedsOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT03317899 | Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma | completed | Phase 2 | 77 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05700747 | Health Through Activity: A Pilot Study of a Rehabilitation Intervention for People Living With Multiple Myeloma | completed | N/A | 5 | MGH Institute of Health ProfessionsOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05182073 | FT576 in Subjects With Multiple Myeloma | completed | Phase 1 | 31 | Fate TherapeuticsINDUSTRY | 1 | Dec 12, 2025 | clinicaltrials |
| NCT02328014 | Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies | completed | Phase 1 / Phase 2 | 40 | Acerta Pharma BVINDUSTRY | 1 | Dec 9, 2025 | clinicaltrials |
| NCT05065866 | Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy | completed | Phase 1 | 14 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT04830046 | Covid-19 Vaccine Responsiveness in MM and Waldenstrom | completed | — | 146 | Massachusetts General HospitalOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT04783038 | Determining The Impact Of Distance Reiki On Patient Reported QOL And Immunity Among Multiple Myeloma Patients | completed | N/A | 30 | Mayo ClinicOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT05511428 | Home Based Daratumumab Administration for Patients With Multiple Myeloma | completed | Phase 4 | 20 | Thomas Jefferson UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT02937571 | High Dose Carfilzomib for Newly Diagnosed Myeloma | completed | Phase 1 / Phase 2 | 29 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT02800954 | Value of Macrophage-Colony Stimulating Factor as a New Marker of Bone Lesions in Multiple Myeloma(MCSF-MYELOME) | completed | N/A | 111 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT01526096 | Stem Cell Transplantation for Patients With Multiple Myeloma | completed | Phase 1 | 30 | University of ChicagoOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT02199665 | Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma(SINE) | completed | Phase 1 | 52 | University of ChicagoOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT01760655 | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies | completed | Phase 2 | 62 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT05961215 | Scalp Cooling to Prevent Hair Loss in Patients Undergoing Stem Cell Transplantation for Multiple Myeloma | completed | N/A | 31 | Cedars-Sinai Medical CenterOTHER | 1 | Oct 27, 2025 | clinicaltrials |
| NCT01592370 | An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 320 | Bristol-Myers SquibbINDUSTRY | 6 | Oct 22, 2025 | clinicaltrials |
| NCT03602235 | High Dose Ascorbic Acid for Plasma Cell Disorders | completed | Phase 1 | 6 | Christopher StrouseOTHER | 1 | Oct 21, 2025 | clinicaltrials |
| NCT03767257 | A Study of Colesevelam for Lenalidomide-Associated Diarrhea | completed | Phase 2 | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 21, 2025 | clinicaltrials |
| NCT02252172 | Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma | completed | Phase 3 | 737 | Janssen Research & Development, LLCINDUSTRY | 13 | Oct 20, 2025 | clinicaltrials |
| NCT02412228 | Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma | completed | Phase 2 | 12 | John L. ReaganOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT07206810 | A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients | completed | — | 419 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Oct 3, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 18, 2026source: clinicaltrials